The Efficacy and Safety of Denosumab for Treating Giant Cell Tumor of Bone: A Systematic Review and Meta-Analysis

Le résumé fourni par la source

The adjuvant treatment of denosumab for the management of giant cell tumor of bone (GCTB) has been widely investigated. However, the inconclusive findings were observed. Therefore, our study aimed to assess the efficacy of denosumab for the adjuvant therapy in the management of GCTB. We conducted a meta-analysis study during the period of FebruaryAugust. Article search was conducted in PubMed, ScienceDirect, and Cochrane library. The predictor was denosumab administration, and the outcomes measures were local recurrence, blood loss, Musculoskeletal Tumor Society (MSTS) score, lung metastase, and malignant transformation. Data were analyzed using Z test to evaluate the association. We included 11 papers, consisting of 253 cases and 1,145 controls. The quality of the included article was evaluated using the Newcastle-Ottawa scale (NOS). Our results identified that denosumab administration was associated with lower blood loss and improved MSTS score compared to those without denosumab administration in patients with GCTB. However, GCTB patients with and without denosumab administration shared similar findings in the context of local recurrence, lung metastase, and malignant transformation. Our study has verified that denosumab administration as an adjuvant treatment for the management of GCTB is associated with lower blood loss during surgical procedure and improved MSTS score.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.